Cooperative Agreement U54CA149145

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to determine the molecular credentials and selection of cancer models to guide translational and clinical applications using single-cell RNA-seq data. The $585,931 award to the University of Pittsburgh will: Identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer. Perform subclone-based congruence and selection for cancer...

This $543,221 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the Albert Einstein College of Medicine to study the cellular and molecular mechanisms underlying lineage plasticity in basal-like breast cancer (BLBC). The key objectives are to: Define the critical de-differentiated cell states driving BLBC progression and explore therapeutic strategies to target these cells for cancer interception. This involves using mouse...

This $230,010 project grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to unravel the drivers of metastasis in small cell lung cancer (SCLC) using human pluripotent stem cell-based models. The research strategy integrates stem cell-derived SCLC models, clinical samples, patient-derived xenografts, and advanced technologies like single-cell sequencing to examine cell behavior in primary tumors and metastatic sites....

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $122,032 to Weill Medical College of Cornell University to conduct research focused on understanding the role of aberrant splicing and isoform expression in cancer cell heterogeneity and its potential as a target for cancer immunotherapy. The research aims to: 1) Characterize mutations in splicing factors and identify tumor-specific isoforms in myelodysplastic syndromes, 2) Explore...

The University of California, Irvine was awarded a $2,186,372 five-year Project Grant under the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program. The grant, titled "Tipping Points in Cancer", will address fundamental questions about cancer initiation and progression through three team-oriented research projects. The projects will investigate cell states, cell-cell interactions, and non-genetic transitions that drive the progression from pre-malignant to...

This $648,428 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Leland Stanford Junior University supports research to identify biomarkers and features of the tumor microenvironment that drive the progression from ductal carcinoma in situ (DCIS) to invasive breast cancer. The key objectives are to: Use in vivo analysis, in vitro 3D culture models, and computational methods to identify features of the DCIS cells, collagen stroma,...

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), will fund the development of MODEX - a cloud-based, centralized health economic model marketplace. The goal is to reduce costs and enhance equity in cancer research and decision-making. The $357,371 award will support the creation of a functional prototype of the MODEX platform, which will serve as an open-source exchange for validated health economic...

This Project Grant award from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program provides $160,330 to the University of Illinois to develop novel lung adenocarcinoma models using genome-edited primary human lung stem and progenitor cells. The goal is to create organoid and in vivo tumor models that better capture the initiation, progression, and composition of primary human lung adenocarcinoma compared to existing mouse models. The researchers will introduce...

This $444,952 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of California, San Diego (UC San Diego) to investigate the role of APOBEC3C and ADAR1 deaminase enzymes in driving the progression of myeloproliferative neoplasms (MPNs) to secondary acute myeloid leukemia (sAML). The research aims to elucidate how deregulation of DNA and RNA editing by these enzymes fuels the transformation of pre-leukemic stem cells...